Bare lymphocyte syndrome: An opportunity to discover our immune system

Immunology Letters

Volumn 141, Issue 2, 2012, Pages 147-157

  Shrestha, Dilip ^a   Szöllosi, János ^a,b   Jenei, Attila ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Bare lymphocyte syndrome; Class II trans activator; HLA; MHC; Regulatory factor X complex; Transporter associated with antigen processing

Indexed keywords

BETA 2 MICROGLOBULIN; CD1D ANTIGEN; CLASS II TRANS ACTIVATOR; COMPLEX REGULATORY FACTOR X ASSOCIATED PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; REGULATORY FACTOR X; REGULATORY FACTOR X 5; REGULATORY FACTOR X ASSOCIATED PROTEIN CONTAINING DANKYRIN REPEAT; TAPASIN; TRANSCRIPTION FACTOR; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; BARE LYMPHOCYTE SYNDROME; BARE LYMPHOCYTE SYNDROME TYPE 1; BARE LYMPHOCYTE SYNDROME TYPE 2; BARE LYMPHOCYTE SYNDROME TYPE 3; BONE MARROW TRANSPLANTATION; CELL MEMBRANE; CELL SURFACE; CONSERVATIVE TREATMENT; DISEASE CLASSIFICATION; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC REGULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; REVIEW; TISSUE REGENERATION; TRANSCRIPTION REGULATION; TRANSPLANTATION;

ANIMALS; ANTIGEN PRESENTATION; HLA ANTIGENS; HUMANS; IMMUNE SYSTEM; REGENERATIVE MEDICINE; SEVERE COMBINED IMMUNODEFICIENCY; TRANSCRIPTIONAL ACTIVATION; TRANSPLANTATION IMMUNOLOGY;

EID: 84855912630     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.10.007     Document Type: Review

References (152)

1. Touraine J.L. The bare lymphocyte syndrome. Combined immune deficiency by absence of HLA antigen expression. Presse Med 1984, 13:671-674.
2. Nekrep N., Fontes J.D., Geyer M., Peterlin B.M. When the lymphocyte loses its clothes. Immunity 2003, 18:453-457.
3. von Boehmer H., Kisielow P. Self-nonself discrimination by T cells. Science 1990, 248:1369-1373.
4. Jiang H., Chess L. Chapter 2 how the immune system achieves self-nonself discrimination during adaptive immunity. Adv Immunol 2009, 102:95-133.
5. Logunova N.N., Viret C., Pobezinsky L.A., Miller S.A., Kazansky D.B., Sundberg J.P., et al. Restricted MHC-peptide repertoire predisposes to autoimmunity. J Exp Med 2005, 202:73-84.
6. Sommer S. The importance of immune gene variability (MHC) in evolutionary ecology and conservation. Front Zool 2005, 2:16.
7. Zimmer J., Andres E., Donato L., Hanau D., Hentges F., de la Salle H. Clinical and immunological aspects of HLA class I deficiency. QJM 2005, 98:719-727.
8. Cerundolo V., de la Salle H. Description of HLA class I- and CD8-deficient patients: insights into the function of cytotoxic T lymphocytes and NK cells in host defense. Semin Immunol 2006, 18:330-336.
9. Casper J.T., Ash R.A., Kirchner P., Hunter J.B., Havens P.L., Chusid M.J. Successful treatment with an unrelated-donor bone marrow transplant in an HLA-deficient patient with severe combined immune deficiency (" bare lymphocyte syndrome" ). J Pediatr 1990, 116:262-265.
10. Godthelp B.C., Van Eggermond M.C., Van Tol M.J., Vossen J.M., van den Elsen P.J. T cell immune reconstitution after allogeneic bone marrow transplantation in bare lymphocyte syndrome. Hum Immunol 2000, 61:898-907.
11. Klein C., Cavazzana-Calvo M., Le Deist F., Jabado N., Benkerrou M., Blanche S., et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood 1995, 85:580-587.
12. Touraine J.L., Betuel H., Souillet G., Jeune M. Combined immunodeficiency disease associated with absence of cell-surface HLA-A and -B antigens. J Pediatr 1978, 93:47-51.
13. Niinaka T., Okochi T., Watanabe Y., Sakai S., Takahashi Y., Yamamura Y. Lymphocyte functions in Wegener's granulomatosis. J Med 1978, 9:491-501.
14. Touraine J.L., Betuel H. Immunodeficiency diseases and expression of HLA antigens. Hum Immunol 1981, 2:147-153.
15. Touraine J.L., Betuel H. The bare lymphocyte syndrome: immunodeficiency resulting from the lack of expression of HLA antigens. Birth Defects Orig Artic Ser 1983, 19:83-85.
16. Raghavan M. Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. J Clin Invest 1999, 103:595-596.
17. Steimle V., Otten L.A., Zufferey M., Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993, 75:135-146.
18. Kovats S., Drover S., Marshall W.H., Freed D., Whiteley P.E., Nepom G.T., et al. Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome. J Exp Med 1994, 179:2017-2022.
19. Gadola S.D., Moins-Teisserenc H.T., Trowsdale J., Gross W.L., Cerundolo V. TAP deficiency syndrome. Clin Exp Immunol 2000, 121:173-178.
20. Sullivan K.E., Stobo J.D., Peterlin B.M. Molecular analysis of the bare lymphocyte syndrome. J Clin Invest 1985, 76:75-79.
21. Reith W., Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001, 19:331-373.
22. Sabatier C., Gimenez C., Calin-Laurens V., Rabourdin-Combe C., Touraine J.L. Type III bare lymphocyte syndrome: lack of HLA class II gene expression and reduction in HLA class I gene expression. C R Acad Sci III 1996, 319:789-798.
23. Ersoy F., Sanal O., Tezcan I., Yel L., Metin A. Bare lymphocyte syndrome with lack of HLA class I and II antigens. Presentation of two cases. Turk J Pediatr 1995, 37:141-146.
24. Schuurman R.K., van Rood J.J., Vossen J.M., Schellekens P.T., Feltkamp-Vroom T.M., Doyer E., et al. Failure of lymphocyte-membrane HLA-A and -B expression in two siblings with combined immunodeficiency. Clin Immunol Immunopathol 1979, 14:418-434.
25. Sun J.C. Re-educating natural killer cells. J Exp Med 2010, 207:2049-2052.
26. Teisserenc H., Schmitt W., Blake N., Dunbar R., Gadola S., Gross W.L., et al. A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett 1997, 57:183-187.
27. Moins-Teisserenc H.T., Gadola S.D., Cella M., Dunbar P.R., Exley A., Blake N., et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 1999, 354:1598-1603.
28. Ritz U., Seliger B. The transporter associated with antigen processing (TAP): structural integrity, expression, function, and its clinical relevance. Mol Med 2001, 7:149-158.
29. Thirdborough S.M., Roddick J.S., Radcliffe J.N., Howarth M., Stevenson F.K., Elliott T. Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide-MHC class I complexes. Eur J Immunol 2008, 38:364-369.
30. Yabe T., Kawamura S., Sato M., Kashiwase K., Tanaka H., Ishikawa Y., et al. A subject with a novel type I bare lymphocyte syndrome has tapasin deficiency due to deletion of 4 exons by Alu-mediated recombination. Blood 2002, 100:1496-1498.
31. Sesma L., Galocha B., Vazquez M., Purcell A.W., Marcilla M., McCluskey J., et al. Qualitative and quantitative differences in peptides bound to HLA-B27 in the presence of mouse versus human tapasin define a role for tapasin as a size-dependent peptide editor. J Immunol 2005, 174:7833-7844.
32. Lehner P.J., Surman M.J., Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line.220. Immunity 1998, 8:221-231.
33. Barnden M.J., Purcell A.W., Gorman J.J., McCluskey J. Tapasin-mediated retention and optimization of peptide ligands during the assembly of class I molecules. J Immunol 2000, 165:322-330.
34. de la Salle H., Hanau D., Fricker D., Urlacher A., Kelly A., Salamero J., et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 1994, 265:237-241.
35. Touraine J.L., Betuel H., Souillet G., Jeune M. Combined immunodeficiency disease associated with absence of cell surface HLA-A and -B. Lancet 1978, 1:319-320.
36. Payne R., Brodsky F.M., Peterlin B.M., Young L.M. " Bare lymphocytes" without immunodeficiency. Hum Immunol 1983, 6:219-227.
37. Caversaccio M., Bonel H.M., Carter R., Williams A.P., Gadola S.D. TAP deficiency syndrome: chronic rhinosinusitis and conductive hearing loss. Eur Arch Otorhinolaryngol 2008, 265:1289-1292.
38. Villa-Forte A., de la Salle H., Fricker D., Hentges F., Zimmer J. HLA class I deficiency syndrome mimicking Wegener's granulomatosis. Arthritis Rheum 2008, 58:2579-2582.
39. Dogu F., Ikinciogullari A., Fricker D., Bozdogan G., Aytekin C., Ileri M., et al. A novel mutation for TAP deficiency and its possible association with Toxoplasmosis. Parasitol Int 2006, 55:219-222.
40. Espana A., Gonzalez-Santesteban C., Martinez-Martinez L., Bauza A., de la Calle-Martin O. A novel mutation in the TAP2 gene in bare lymphocyte syndrome: association with metastatic cutaneous squamous cell carcinoma. Arch Dermatol 2010, 146:96-98.
41. Lou Y., Basha G., Seipp R.P., Cai B., Chen S.S., Moise A.R., et al. Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival. Clin Cancer Res 2008, 14:1494-1501.
42. Belicha-Villanueva A., McEvoy S., Cycon K., Ferrone S., Gollnick S.O., Bangia N. Differential contribution of TAP and tapasin to HLA class I antigen expression. Immunology 2008, 124:112-120.
43. de la Salle H., Donato L., Hanau D. Peptide transporter defects in human leukocyte antigen class I deficiency. Primary immunodeficiency diseases: a molecular and genetic approach 2007, 242-250. Oxford University Press, New York. H.D. Ochs, E.C.I. Smith, J.M. Puck (Eds.).
44. Maeda H., Hirata R., Chen R.F., Suzaki H., Kudoh S., Tohyama H. Defective expression of HLA class I antigens: a case of the bare lymphocyte without immunodeficiency. Immunogenetics 1985, 21:549-558.
45. de la Salle H., Zimmer J., Fricker D., Angenieux C., Cazenave J.P., Okubo M., et al. HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest 1999, 103:R9-R13.
46. Plebani A., Monafo V., Cattaneo R., Carella G., Brugnoni D., Facchetti F., et al. Defective expression of HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers. J Am Acad Dermatol 1996, 35:814-818.
47. Matamoros N., Mila J., Llano M., Balas A., Vicario J.L., Pons J., et al. Molecular studies and NK cell function of a new case of TAP2 homozygous human deficiency. Clin Exp Immunol 2001, 125:274-282.
48. Markel G., Mussaffi H., Ling K.L., Salio M., Gadola S., Steuer G., et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 2004, 103:1770-1778.
49. Sugiyama Y., Maeda H., Okumura K., Takaku F. Progressive sinobronchiectasis associated with the " bare lymphocyte syndrome" in an adult. Chest 1986, 89:398-401.
50. de la Salle H., Saulquin X., Mansour I., Klayme S., Fricker D., Zimmer J., et al. Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol 2002, 128:525-531.
51. Lee S., Park B., Kang K., Ahn K. Redox-regulated export of the major histocompatibility complex class I-peptide complexes from the endoplasmic reticulum. Mol Biol Cell 2009, 20:3285-3294.
52. Meissner T.B., Li A., Biswas A., Lee K.H., Liu Y.J., Bayir E., et al. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci USA 2010, 107:13794-13799.
53. Choi H.J., Xu H., Geng Y., Colmone A., Cho H., Wang C.R. Bacterial infection alters the kinetics and function of iNKT cell responses. J Leukoc Biol 2008, 84:1462-1471.
54. Yuan W., Dasgupta A., Cresswell P. Herpes simplex virus evades natural killer T cell recognition by suppressing CD1d recycling. Nat Immunol 2006, 7:835-842.
55. + T cell priming in Toxoplasma gondii infection by controlling NK cell IFN-γ production. J Exp Med 2007, 204:2591-2602.
56. Klein C., Lisowska-Grospierre B., LeDeist F., Fischer A., Griscelli C. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr 1993, 123:921-928.
57. Reith W., Lisowska-Grospierre B., Fischer A. Molecular basis of major histocompatibility complex class II deficiency. Primary immunodeficiency diseases: a molecular and genetic approach 2007, 227-241. Oxford University Press, New York. H.D. Ochs, E.C.I. Smith, J.M. Puck (Eds.).
58. Gelin C., Sloma I., Charron D., Mooney N. Regulation of MHC II and CD1 antigen presentation: from ubiquity to security. J Leukoc Biol 2009, 85:215-224.
59. de Preval C., Lisowska-Grospierre B., Loche M., Griscelli C., Mach B. A trans-acting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes. Nature 1985, 318:291-293.
60. Kara C.J., Glimcher L.H. Three in vivo promoter phenotypes in MHC class II deficient combined immunodeficiency. Immunogenetics 1993, 37:227-230.
61. Krawczyk M., Reith W. Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease. Tissue Antigens 2006, 67:183-197.
62. Accolla R.S., Carra G., Guardiola J. Reactivation by a trans-acting factor of human major histocompatibility complex Ia gene expression in interspecies hybrids between an Ia-negative human B-cell variant and an Ia-positive mouse B-cell lymphoma. Proc Natl Acad Sci USA 1985, 82:5145-5149.
63. Benichou B., Strominger J.L. Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis. Proc Natl Acad Sci USA 1991, 88:4285-4288.
64. Matheux F., Villard J. Cellular and gene therapy for major histocompatibility complex class II deficiency. News Physiol Sci 2004, 19:154-158.
65. Dziembowska M., Fondaneche M.C., Vedrenne J., Barbieri G., Wiszniewski W., Picard C., et al. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency. Immunogenetics 2002, 53:821-829.
66. Wiszniewski W., Fondaneche M.C., Le Deist F., Kanariou M., Selz F., Brousse N., et al. Mutation in the class II trans-activator leading to a mild immunodeficiency. J Immunol 2001, 167:1787-1794.
67. Accolla R.S., Mazza S., De Lerma Barbaro A., De Maria A., Tosi G. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication. Eur J Immunol 2002, 32:2783-2791.
68. Tosi G., Forlani G., Andresen V., Turci M., Bertazzoni U., Franchini G., et al. The MHC-II transactivator CIITA, a viral restriction factor targeting human T-cell lymphotropic virus type 1 Tax-1 function and inhibiting viral replication. J Virol 2011.
69. Casoli C., De Lerma Barbaro A., Pilotti E., Bertazzoni U., Tosi G., Accolla R.S. The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2. Blood 2004, 103:995-1001.
70. Reith W., LeibundGut-Landmann S., Waldburger J.M. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 2005, 5:793-806.
71. Li J., Mahajan A., Tsai M.D. Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry 2006, 45:15168-15178.
72. Wiszniewski W., Fondaneche M.C., Lambert N., Masternak K., Picard C., Notarangelo L., et al. Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B. Immunogenetics 2000, 51:261-267.
73. Naamane H., El Maataoui O., Ailal F., Barakat A., Bennani S., Najib J., et al. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population. Eur J Pediatr 2010, 169:1069-1074.
74. Lennon-Dumenil A.M., Barbouche M.R., Vedrenne J., Prod'Homme T., Bejaoui M., Ghariani S., et al. Uncoordinated HLA-D gene expression in a RFXANK-defective patient with MHC class II deficiency. J Immunol 2001, 166:5681-5687.
75. Garvie C.W., Stagno J.R., Reid S., Singh A., Harrington E., Boss J.M. Characterization of the RFX complex and the RFX5(L66A) mutant: implications for the regulation of MHC class II gene expression. Biochemistry 2007, 46:1597-1611.
76. Steimle V., Durand B., Barras E., Zufferey M., Hadam M.R., Mach B., et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995, 9:1021-1032.
77. Nekrep N., Jabrane-Ferrat N., Wolf H.M., Eibl M.M., Geyer M., Peterlin B.M. Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome. Nat Immunol 2002, 3:1075-1081.
78. Villard J., Lisowska-Grospierre B., van den Elsen P., Fischer A., Reith W., Mach B. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency. N Engl J Med 1997, 337:748-753.
79. Durand B., Sperisen P., Emery P., Barras E., Zufferey M., Mach B., et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 1997, 16:1045-1055.
80. van Eggermond M.C., Tezcan I., Heemskerk M.H., van den Elsen P.J. Transcriptional silencing of RFXAP in MHC class II-deficiency. Mol Immunol 2008, 45:2920-2928.
81. Ni Z., Abou El Hassan M., Xu Z., Yu T., Bremner R. The chromatin-remodeling enzyme BRG1 coordinates CIITA induction through many interdependent distal enhancers. Nat Immunol 2008, 9:785-793.
82. Bhat K.P., Truax A.D., Brooks J.K., Greer S.F. Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression. Immunol Cell Biol 2010.
83. Choi N.M., Majumder P., Boss J.M. Regulation of major histocompatibility complex class II genes. Curr Opin Immunol 2010.
84. Rimsza L.M., Chan W.C., Gascoyne R.D., Campo E., Jaffe E.S., Staudt L.M., et al. CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica 2009, 94:596-598.
85. Will N., Seger R.A., Betzler C., Dockter G., Graf N., Buttner M., et al. Bare lymphocyte syndrome-combined immunodeficiency and neutrophil dysfunction. Eur J Pediatr 1990, 149:700-704.
86. Cressman D.E., Chin K.C., Taxman D.J., Ting J.P. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity 1999, 10:163-171.
87. DeSandro A., Nagarajan U.M., Boss J.M. The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. Am J Hum Genet 1999, 65:279-286.
88. Schmetterer K.G., Seidel M.G., Kormoczi U., Rottal A., Schwarz K., Matthes-Martin S., et al. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels. Int Arch Allergy Immunol 2010, 152:390-400.
89. Bontron S., Steimle V., Ucla C., Eibl M.M., Mach B. Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A. Hum Genet 1997, 99:541-546.
90. Peijnenburg A., Van den Berg R., Van Eggermond M.J., Sanal O., Vossen J.M., Lennon A.M., et al. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene. Immunogenetics 2000, 51:42-49.
91. Quan V., Towey M., Sacks S., Kelly A.P. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA. Immunogenetics 1999, 49:957-963.
92. Masternak K., Barras E., Zufferey M., Conrad B., Corthals G., Aebersold R., et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998, 20:273-277.
93. Wiszniewski W., Fondaneche M.C., Louise-Plence P., Prochnicka-Chalufour A., Selz F., Picard C., et al. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. Immunogenetics 2003, 54:747-755.
94. Nagarajan U.M., Louis-Plence P., DeSandro A., Nilsen R., Bushey A., Boss J.M. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 1999, 10:153-162.
95. Brickey W.J., Wright K.L., Zhu X.S., Ting J.P. Analysis of the defect in IFN-γ induction of MHC class II genes in G1B cells: identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor. J Immunol 1999, 163:6622-6630.
96. Villard J., Reith W., Barras E., Gos A., Morris M.A., Antonarakis S.E., et al. Analysis of mutations and chromosomal localisation of the gene encoding RFX5, a novel transcription factor affected in major histocompatibility complex class II deficiency. Hum Mutat 1997, 10:430-435.
97. Peijnenburg A., Van Eggermond M.C., Van den Berg R., Sanal O., Vossen J.M., Van den Elsen P.J. Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene. Immunogenetics 1999, 49:338-345.
98. Peijnenburg A., Van Eggermond M.J., Gobin S.J., Van den Berg R., Godthelp B.C., Vossen J.M., et al. Discoordinate expression of invariant chain and MHC class II genes in class II transactivator-transfected fibroblasts defective for RFX5. J Immunol 1999, 163:794-801.
99. Fondaneche M.C., Villard J., Wiszniewski W., Jouanguy E., Etzioni A., Le Deist F., et al. Genetic and molecular definition of complementation group D in MHC class II deficiency. Hum Mol Genet 1998, 7:879-885.
100. Rousseau P., Masternak K., Krawczyk M., Reith W., Dausset J., Carosella E.D., et al. In vivo, RFX5 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class I protein expression in a cell type-dependent manner. Immunology 2004, 111:53-65.
101. Long A.B., Ferguson A.M., Majumder P., Nagarajan U.M., Boss J.M. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression. Mol Immunol 2006, 43:395-409.
102. van den Elsen P.J., Peijnenburg A., van Eggermond M.C., Gobin S.J. Shared regulatory elements in the promoters of MHC class I and class II genes. Immunol Today 1998, 19:308-312.
103. Nagarajan U.M., Peijnenburg A., Gobin S.J., Boss J.M., van den elsen P.J. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells. J Immunol 2000, 164:3666-3674.
104. Al-Mousa H., Al-Shammari Z., Al-Ghonaium A., Al-Dhekri H., Al-Muhsen S., Al-Saud B., et al. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency. Biol Blood Marrow Transplant 2010, 16:818-823.
105. Lambert M., Van Eggermond M., Mascart F., Dupont E., Van den Elsen P. TCR V α- and V β-gene segment use in T-cell subcultures derived from a type-III bare lymphocyte syndrome patient deficient in MHC class-II expression. Dev Immunol 1992, 2:227-236.
106. + T cells: unrestricted Vβ gene usage with CDR3 size limitations. Transplantation 2003, 75:514-521.
107. Beilke J.N., Kuhl N.R., Van Kaer L., Gill R.G. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat Med 2005, 11:1059-1065.
108. Beilke J.N., Gill R.G. Frontiers in nephrology: the varied faces of natural killer cells in transplantation-contributions to both allograft immunity and tolerance. J Am Soc Nephrol 2007, 18:2262-2267.
109. Wang B., Chun T., Rulifson I.C., Exley M., Balk S.P., Wang C.R. Human CD1d functions as a transplantation antigen and a restriction element in mice. J Immunol 2001, 166:3829-3836.
110. Culver D.A., Newman L.S., Kavuru M.S. Gene-environment interactions in sarcoidosis: challenge and opportunity. Clin Dermatol 2007, 25:267-275.
111. Capittini C., Martinetti M., Cuccia M. MHC variation, mate choice and natural selection: the scent of evolution. Riv Biol 2008, 101:463-480.
112. Hermann R., Knip M., Veijola R., Simell O., Laine A.P., Akerblom H.K., et al. Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes-indication of an increased environmental pressure?. Diabetologia 2003, 46:420-425.
113. de la Fuente H., Mittelbrunn M., Sanchez-Martin L., Vicente-Manzanares M., Lamana A., Pardi R., et al. Synaptic clusters of MHC class II molecules induced on DCs by adhesion molecule-mediated initial T-cell scanning. Mol Biol Cell 2005, 16:3314-3322.
114. Wang Y., Shibuya K., Yamashita Y., Shirakawa J., Shibata K., Kai H., et al. LFA-1 decreases the antigen dose for T cell activation in vivo. Int Immunol 2008, 20:1119-1127.
115. Gombos I., Detre C., Vamosi G., Matko J. Rafting MHC-II domains in the APC (presynaptic) plasma membrane and the thresholds for T-cell activation and immunological synapse formation. Immunol Lett 2004, 92:117-124.
116. Suzuki J., Yamasaki S., Wu J., Koretzky G.A., Saito T. The actin cloud induced by LFA-1-mediated outside-in signals lowers the threshold for T-cell activation. Blood 2007, 109:168-175.
117. Kelly M.A., Mijovic C.H., Barnett A.H. Genetics of type 1 diabetes. Best Pract Res Clin Endocrinol Metab 2001, 15:279-291.
118. Sanjeevi C.B., Sedimbi S.K., Landin-Olsson M., Kockum I., Lernmark A. Risk conferred by HLA-DR and DQ for type 1 diabetes in 0-35-year age group in Sweden. Ann NY Acad Sci 2008, 1150:106-111.
119. Feitsma A.L., van der Helm-van Mil A.H., Huizinga T.W., de Vries R.R., Toes R.E. Protection against rheumatoid arthritis by HLA: nature and nurture. Ann Rheum Dis 2008, 67(Suppl. 3):iii61-iii63.
120. Teufel A., Worns M., Weinmann A., Centner C., Piendl A., Lohse A.W., et al. Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. World J Gastroenterol 2006, 12:5513-5516.
121. Ban Y., Davies T.F., Greenberg D.A., Concepcion E.S., Tomer Y. The influence of human leucocyte antigen (HLA) genes on autoimmune thyroid disease (AITD): results of studies in HLA-DR3 positive AITD families. Clin Endocrinol (Oxf) 2002, 57:81-88.
122. Boehm B.O., Kuhnl P., Manfras B.J., Chen M., Lee J.C., Holzberger G., et al. HLA-DRB3 gene alleles in Caucasian patients with Graves' disease. Clin Investig 1992, 70:956-960.
123. Karinen H., Karkkainen P., Pihlajamaki J., Janatuinen E., Heikkinen M., Julkunen R., et al. Gene dose effect of the DQB1*0201 allele contributes to severity of coeliac disease. Scand J Gastroenterol 2006, 41:191-199.
124. Rezaieyazdi Z., Tavakkol-Afshari J., Esmaili E., Orouji E., Pezeshkpour F., Khodadoost M., et al. Association of HLA-DQB1 allelic sequence variation with susceptibility to systemic lupus erythematosus. Iran J Allergy Asthma Immunol 2008, 7:91-95.
125. Boyton R.J. Regulation of immunity in bronchiectasis. Med Mycol 2009, 47(Suppl. 1):S175-S182.
126. Niks E.H., Kuks J.B., Roep B.O., Haasnoot G.W., Verduijn W., Ballieux B.E., et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006, 66:1772-1774.
127. Raju R., Spack E.G., David C.S. Acetylcholine receptor peptide recognition in HLA DR3-transgenic mice: in vivo responses correlate with MHC-peptide binding. J Immunol 2001, 167:1118-1124.
128. Lan N.T., Kikuchi M., Huong V.T., Ha do Q., Thuy T.T., Tham V.D., et al. Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome. PLoS Negl Trop Dis 2008, 2:e304.
129. Sugita M., Porcelli S.A., Brenner M.B. Assembly and retention of CD1b heavy chains in the endoplasmic reticulum. J Immunol 1997, 159:2358-2365.
130. 2-microglobulin. J Biol Chem 2006, 281:40369-40378.
131. Chiu Y.H., Park S.H., Benlagha K., Forestier C., Jayawardena-Wolf J., Savage P.B., et al. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat Immunol 2002, 3:55-60.
132. Rieder S.A., Nagarkatti P., Nagarkatti M. CD1d-independent activation of iNKT cells by staphylococcal enterotoxin B through MHCII/TCR interaction results in acute lung injury. Infect Immun 2011.
133. Jayawardena-Wolf J., Benlagha K., Chiu Y.H., Mehr R., Bendelac A. CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain. Immunity 2001, 15:897-908.
134. Mohammadi J., Pourpak Z., Jarefors S., Saghafi S., Zendehdel K., Pourfathollah A.A., et al. Human leukocyte antigens (HLA) associated with selective IgA deficiency in Iran and Sweden. Iran J Allergy Asthma Immunol 2008, 7:209-214.
135. Mills K.H. Regulatory T cells: friend or foe in immunity to infection?. Nat Rev Immunol 2004, 4:841-855.
136. + T cells and reduces chronic retroviral set points. Proc Natl Acad Sci USA 2011, 108:2420-2425.
137. Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
138. +T lymphocytes from MHC class II-deficient mice exhibit regulatory activity. J Immunol 2005, 175:246-253.
139. McCormack M.P., Rabbitts T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004, 350:913-922.
140. Yu S.F., von Ruden T., Kantoff P.W., Garber C., Seiberg M., Ruther U., et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986, 83:3194-3198.
141. Ma Y., Ramezani A., Lewis R., Hawley R.G., Thomson J.A. High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells 2003, 21:111-117.
142. Brown M.P., Topham D.J., Sangster M.Y., Zhao J., Flynn K.J., Surman S.L., et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med 1998, 4:1253-1260.
143. Chen G., Wu D., Wang Y., Cen J., Feng Y., Sun A., et al. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2008, 81:226-235.
144. Chen X., Jensen P.E. MHC class II antigen presentation and immunological abnormalities due to deficiency of MHC class II and its associated genes. Exp Mol Pathol 2008, 85:40-44.
145. 2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance. Melanoma Res 1997, 7(Suppl. 2):S67-S74.
146. 2-microglobulin genes. Cancer Immunol Immunother 2009, 58:395-408.
147. 2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 2007, 121:454-458.
148. Johnsen A.K., France J., Nagy N., Askew D., Abdul-Karim F.W., Gerson S.L., et al. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence. Int J Cancer 2001, 91:366-372.
149. van den Elsen P.J., van der Stoep N. Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?. Am J Pathol 2003, 163:373-375. [author reply 375-6].
150. Choi Y.E., Yu H.N., Yoon C.H., Bae Y.S. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter. Eur J Immunol 2009, 39:858-868.
151. Johnsen A.K., Templeton D.J., Sy M., Harding C.V. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999, 163:4224-4231.
152. Cui J., Zhu L., Xia X., Wang H.Y., Legras X., Hong J., et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 2010, 141:483-496.